Loading...
01/11 11:29
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights positive developments like successful inspections, strong market interest, and strategic partnerships. Despite increased expenses, the company shows financial improvement and a strong cash position. The Q&A reveals confidence in FDA processes and pricing strategies. The market opportunity for D-PLEX100 is significant, with plans for expansion and premium pricing potential. While some details were unclear, the overall sentiment is positive, suggesting potential stock price growth in the short term.
Research and Development (R&D) Expenses $5.3 million, down from $6.2 million in the second quarter of 2025 and $6 million in the same quarter last year. This decrease reflects the completion of the SHIELD II Phase III trial.
General and Administrative (G&A) Expenses $1.8 million compared to $1.2 million in the third quarter of 2024. The increase was primarily due to noncash expenses related to performance-based options or PSUs, following the successful SHIELD II Phase III trial, which triggered the vesting of the PSUs.
Marketing and Business Development Expenses $0.4 million, up from $0.2 million in the same period last year. The increase was primarily due to noncash expenses related to performance-based options or PSUs, following the successful SHIELD II Phase III trial, which triggered the vesting of the PSUs.
Net Loss for the Quarter $7.5 million or $0.37 per share, an improvement from the net loss of $7.8 million or $1.22 per share in the third quarter of 2024.
R&D Expenses for 9 Months Ended September 30, 2025 $17.6 million compared to $15.8 million in the prior year period. The increase reflects ongoing development activities.
G&A Expenses for 9 Months Ended September 30, 2025 $5.4 million from $3.3 million last year. The increase was primarily due to noncash expenses related to performance-based options or PSUs, following the successful SHIELD II Phase III trial, which triggered the vesting of the PSUs.
Marketing and Business Development Expenses for 9 Months Ended September 30, 2025 $1.4 million from $0.7 million last year. The increase was primarily due to noncash expenses related to performance-based options or PSUs, following the successful SHIELD II Phase III trial, which triggered the vesting of the PSUs.
Net Loss for 9-Month Period $25.7 million or $1.72 per share compared to $20.5 million or $3.82 per share for the same period in 2024.
Cash, Cash Equivalents, and Short-Term Deposits $18.8 million as of September 30, 2025, up from $15.6 million at year-end 2024.
Debt Reduction Current maturities decreased from $6.5 million to $2.4 million during the quarter.
D-PLEX100 NDA Submission: Pre-NDA meeting with FDA scheduled for early December 2025. NDA submission planned for early 2026, leveraging Fast Track and breakthrough therapy designations.
European Market Authorization: Preparing for submission of European marketing authorization application following NDA submission.
GMP Inspection: Successfully completed Israeli Ministry of Health GMP inspection, ensuring readiness for commercial manufacturing for European market and potential FDA inspection.
U.S. Market Access Study: Study validated D-PLEX100's commercial potential. Surgeons and hospital pharmacy directors showed strong interest, with 80% of surgeons likely to use it for eligible patients and 70% of pharmacy directors likely to add it to formulary.
Hospital Adoption: D-PLEX100 expected to be widely adopted, especially for high-risk surgeries. NTAP designation could further enhance adoption.
Financial Performance: Net loss for Q3 2025 was $7.5M, an improvement from $7.8M in Q3 2024. Cash balance of $18.8M as of September 30, 2025, expected to fund operations into 2026. Reduced debt from $6.5M to $2.4M.
R&D and G&A Expenses: R&D expenses decreased to $5.3M in Q3 2025 due to SHIELD II trial completion. G&A expenses increased to $1.8M due to noncash expenses related to performance-based options.
Partnership Discussions: Advanced discussions with potential U.S. partners with hospital sales infrastructure, leveraging SHIELD II trial results.
Pipeline Expansion: Progress in innovative pipeline areas including oncology, obesity, and diabetes.
Regulatory Approval Risks: The company faces risks related to the regulatory approval process for D-PLEX100, including the need to align with the FDA on data package requirements and the potential challenges of passing FDA inspections following the NDA submission.
Commercial Manufacturing Readiness: While the company has completed a GMP inspection in Israel, there is a risk of potential issues arising during future FDA inspections or scaling up manufacturing for commercial production.
Market Adoption Challenges: Despite positive feedback from surgeons and pharmacy directors, there is a risk that hospitals may not adopt D-PLEX100 as widely as anticipated, especially if reimbursement mechanisms like NTAP designation are not secured.
Financial Sustainability: The company reported a net loss of $7.5 million for the quarter and $25.7 million for the 9-month period, which could pose challenges in sustaining operations if cash reserves are depleted before achieving significant revenue.
Competitive Pressures: The company may face competition from existing SSI prevention measures, which could impact the market penetration and commercial success of D-PLEX100.
Anticipated timing of pre-NDA meeting with FDA: Scheduled for early December 2025, expected to be held in-person at the FDA office.
Planned NDA submission for D-PLEX100: On track for early 2026, leveraging Fast Track and breakthrough therapy designations.
European marketing authorization application: Submission expected to follow the NDA submission.
Commercial manufacturing readiness for D-PLEX100: Successfully completed Israeli Ministry of Health GMP inspection, ensuring readiness for European market manufacturing and preparation for FDA inspection.
Strategic discussions with potential U.S. partners: Ongoing discussions with partners having established hospital sales infrastructure, building on positive Phase III SHIELD II trial results.
U.S. market access study findings: Study confirmed strong interest from surgeons and hospital pharmacy directors, with 80% of surgeons likely to use D-PLEX100 for eligible patients and 70% of pharmacy directors likely to add it to formulary.
Expected cash runway: Current cash balance expected to fund operations well into 2026.
The selected topic was not discussed during the call.
The earnings call highlights positive developments like successful inspections, strong market interest, and strategic partnerships. Despite increased expenses, the company shows financial improvement and a strong cash position. The Q&A reveals confidence in FDA processes and pricing strategies. The market opportunity for D-PLEX100 is significant, with plans for expansion and premium pricing potential. While some details were unclear, the overall sentiment is positive, suggesting potential stock price growth in the short term.
The earnings call reveals mixed signals: positive developments like the completion of Phase 3 trials and a strong cash position are offset by increased expenses and net losses. The Q&A highlights uncertainties in the GLP-1 program and partnership milestones. While the company has a promising product and strategic initiatives, financial challenges and competitive market risks temper enthusiasm. Given these factors, the stock price is likely to remain stable, reflecting a neutral sentiment.
The earnings call presents a mixed picture. Financial health shows a net loss increase, raising concerns about sustainability, but the cash runway is extended into Q3 2025. The SHIELD II trial's positive signals and potential NDA submission are promising, yet the lack of finalized pricing and partnership details introduces uncertainty. The Q&A highlighted preparation for NDA filing, but also revealed unclear management responses and potential market risks. Overall, the sentiment is neutral, reflecting both potential and uncertainty without a clear catalyst for significant short-term stock movement.
The earnings call reveals financial challenges with increasing net losses and R&D expenses, raising concerns about financial sustainability. The Q&A highlights uncertainties in pricing strategy and NDA filing, while market risks persist due to competitive pressures. Despite potential positive trial results, the lack of finalized pricing and regulatory risks weigh heavily. The absence of a strong partnership announcement further diminishes short-term optimism, leading to a negative sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
